Proteros and CHDI Foundation, Inc. establish discovery services collaboration to address Huntington’s disease
Proteros Biostructures GmbH (Proteros) announced that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI. Proteros will apply its integrated discovery platform including proprietary x-ray crystallography tools to help CHDI in its mission to develop therapeutics that slow the progression of Huntington’s disease (HD).
Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “CHDI has been at the forefront of using a best-in-class network to assist in developing therapies for HD. We welcome the opportunity for Proteros to contribute to this effort.”
Organizations
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.